Impairment and disability in 20 CIDP patients according to disease activity status. J Peripher Nerv Syst. 2013;18(3):241-6. doi: https://doi. org/10.1111/jns5.12038.Panaite, P.A., Renaud, S., Kraftsik, R., Steck, A.J., Kuntzer, T., 2013. Impairment and disabil- ity in 20 ...
The CIDP disease activity status (CDAS) includes five categories of the disease such as 'unstable active disease,' 'improving,' and 'remission.' Factors considered in categorizing a patient include the neurological status and duration of follow-up. The advantages of using the CDAS, and ...
3 Gorson KC, van Schaik IN, Merkies ISJ, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status, Recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010;15:326–33. (慢性炎性脱髓鞘性多发性神经病变疾病活动状态、临床研究标准建...
3 Gorson KC, van Schaik IN, Merkies ISJ, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status, Recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010;15:326–33. (慢性脫髓鞘多發性神經炎疾病活動狀態、臨床研究標準建議和臨床...
C. et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J. Peripher. Nerv. Syst. 15, 326–333 (2010). Article PubMed Google Scholar Hartung, H. P., Lehmann, H. C. & Willison, H. G...
Abstract Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic autoimmune neuropathy. Despite clinical challenges in diagnosis—owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination...
Panaite PA, Renaud S, Kraftsik R, Steck AJ, Kuntzer T. Impairment and disability in 20 CIDP patients according to disease activity status. J Peripher Nerv Syst. 2013;18(3):241-6. doi: https://doi. org/10.1111/jns5.12038.Panaite, P.A., Renaud, S., Kraftsik, R., Steck, A.J.,...
Methods FORCIDP is a double-blind, randomized, multicenter, placebo-controlled, parallel-group study in ~156-200 adult patients with CIDP and a history of recent disease activity. After randomization (to either fingolimod 0.5 mg daily or placebo) and start of study drug, prior therapy will be...
Alan PestronkotherZaidman CM, Pestronk A. Nerve size in CIDP varies with disease activity and therapy response over time: a retrospective ultrasound study. Muscle Nerve 2014; 50:733-738.Zaidman CM, Pestronk A. Nerve size in CIDP varies with disease activity and therapy response over time: ...